Safety and efficacy of transbronchial cryobiopsy for elderly lung cancer patients DOI Creative Commons

Kumiko Yamatsuta,

Shotaro Okachi, Shin Hasegawa

et al.

BMC Pulmonary Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 26, 2024

The increasing prevalence of lung cancer in the elderly population necessitates a closer evaluation diagnostic and therapeutic approaches. This study aimed to compare safety efficacy transbronchial cryobiopsy (TBLC) between patients ≥ 80 years younger patients. A retrospective review was conducted 96 diagnosed with peripheral who underwent TBLC April 2021 October 2023. were categorized into two groups: group (age years, n = 20) < years; 76). Data regarding biopsy yield, complications, feasibility molecular analyses collected analyzed. yield comparable groups (95% vs. 89.5%, p 0.679). Biomarker testing, including programmed death-ligand 1 expression genetic mutations, feasible all cases using samples. No significant differences observed major complications such as pneumothorax or bleeding. found be safe effective tool for provided adequate samples testing. Since complication rates did not significantly differ age groups, alone should considered contraindication procedure.

Language: Английский

LUNG Year in Review: 2024 DOI Creative Commons
Peter V. Dicpinigaitis

Lung, Journal Year: 2025, Volume and Issue: 203(1)

Published: Jan. 22, 2025

Language: Английский

Citations

0
Safety and efficacy of transbronchial cryobiopsy for elderly lung cancer patients DOI Creative Commons

Kumiko Yamatsuta,

Shotaro Okachi, Shin Hasegawa

et al.

BMC Pulmonary Medicine, Journal Year: 2024, Volume and Issue: 24(1)

Published: Dec. 26, 2024

The increasing prevalence of lung cancer in the elderly population necessitates a closer evaluation diagnostic and therapeutic approaches. This study aimed to compare safety efficacy transbronchial cryobiopsy (TBLC) between patients ≥ 80 years younger patients. A retrospective review was conducted 96 diagnosed with peripheral who underwent TBLC April 2021 October 2023. were categorized into two groups: group (age years, n = 20) < years; 76). Data regarding biopsy yield, complications, feasibility molecular analyses collected analyzed. yield comparable groups (95% vs. 89.5%, p 0.679). Biomarker testing, including programmed death-ligand 1 expression genetic mutations, feasible all cases using samples. No significant differences observed major complications such as pneumothorax or bleeding. found be safe effective tool for provided adequate samples testing. Since complication rates did not significantly differ age groups, alone should considered contraindication procedure.

Language: Английский

Citations

0